Introduction
Plasma creatinine concentration is widely used as a marker of glomerular filtration rate (GFR). In the individual patient, changes in GFR are reflected by inverse changes in plasma creatinine concentration. However, plasma creatinine concentration is inaccurate for predicting actual GFR since creatinine production is highly variable between individuals. Therefore, equations have been developed that allow a more accurate estimation of GFR. These formulas typically include age and gender to accommodate differences in creatinine generation. In recent years, the abbreviated MDRD formula has been introduced in clinical practice and is considered the best available formula [1] . This MDRD formula includes the following variables: plasma creatinine concentration, age, gender and race. Thus, any condition that affects the relationship between plasma creatinine concentration and GFR will affect the accuracy of the MDRD formula as estimate of GFR. We have previously suggested that renal tubular handling of creatinine is altered in patients with a nephrotic syndrome [2] . In a pilot study with a limited number of patients, we observed that creatinine clearance overestimated GFR (measured by inulin clearance) in patients with hypoalbuminaemia.
In the present study, we have evaluated the abbreviated MDRD formula as well as other formulas in a large cohort of patients with proteinuria. We used plasma cystatin C (CysC) and plasma beta-2-microglobulin (β2m) as markers of GFR. The data suggest that the currently used formulas for eGFR may be less valid in patients with a nephrotic syndrome.
Materials and methods
In our centre, patients with recently diagnosed glomerular diseases are evaluated using a standardized protocol as described [3] . In brief, blood samples and timed urine samples are collected for the measurement of plasma creatinine, electrolytes, albumin, urea, β2m, and urinary excretion of creatinine, total protein, β2m and albumin. In addition, aliquots of plasma, plasma and urine are stored at −70˚C. Patient data are collected in a database.
For this study, we have used the data on 180 patients who were entered in the database between 1995 and 2006. In addition, plasma samples of these patients were retrieved, thawed, and used for the measurement of CysC and plasma creatinine. Methods for the determination of albumin, urea and β2m have been described [3] . In our laboratory, the creatinine assay was changed in 2005, and a Jaffé-based technique was replaced by an enzymatic method. Therefore, plasma creatinine concentration was reanalysed in all thawed samples using the Roche enzymatic method (Roche Diagnostics, Creatinine Plus, Indianapolis, IN, USA). CysC was measured using the Dade Behring N latex Cystatin C assay [4] . Although creatinine and CysC can be reliably determined in frozen samples, errors may occur due to effects such as freeze-drying. To avoid such errors, we regularly measure plasma sodium concentrations in thawed samples. Samples with differences in sodium concentration > 3% compared with the original measurement are not included for this study.
Calculations and statistics
Estimated GFR (eGFR) was calculated with the re-expressed four- [5] . We also calculated eGFR by the new CKD-EPI equations using serum creatinine, CysC or both (Table 1) [6, 7] . CKD-EPI-Cr, creatinine-based CKD-EPI equation for eGFR; eGFR, estimated glomerular filtration rate; sCr, serum creatinine (mg/dL); CKD-EPICysC, cystatin C-based CKD-EPI equation for eGFR; CysC, serum cystatin C (mg/L); CKD-EPI-Cr + CysC, CKD-EPI equation for eGFR, based on both serum creatinine and serum cystatin C.
eGFR in the nephrotic syndrome
The correlation between two parameters (non-parametric distributions) was analysed by Spearman's rank coefficient of correlation.
To clarify if the relation between the markers of GFR (CysC and β2m) and eGFR-MDRD4 was influenced by other parameters, we performed univariable and multiple regression analysis. To allow regression analysis, non-parametric parameters were transformed. The dependent variable was the ratio between inversed CysC or β2m, respectively, and eGFR.
The following variables were tested in the regression analysis: age, gender, plasma albumin, plasma urea, proteinuria, weight, BMI and body surface area (BSA). Multiple regression analysis was performed in forward stepwise fashion.
For comparison between multiple variables, we used a non-parametric Kruskal-Wallis test.
All data are presented as means (± SD) or medians (range) when appropriate. All statistics were performed using SPSS software, version 16.0 (Chicago, IL, USA). P < 0.05 was considered significant.
Results
Data of 180 patients with a glomerular disease were available. Sixteen patients (9%) were excluded from analysis because of differences in plasma sodium concentration between original and thawed samples (see Materials and methods section). Ten patients were treated with immunosuppressive agents including steroids, and information on immunosuppressive medication was lacking in 12 patients. Since the use of steroids clearly affects cellular metabolism and lymphocyte survival, and thus will affect production of CysC or β2m, we excluded these patients from the analysis. Baseline characteristics of the remaining patients (n = 142) are shown in Table 2 . All patients were Caucasian, and there were no diabetics. Biopsy-proven renal diseases were membranous nephropathy (n = 66), primary focal segmental glomerulosclerosis (n = 22), IgA nephropathy (n = 23), minimal change nephrotic syndrome (n =11) and others (n = 20). Eighty patients had a nephrotic syndrome (plasma albumin <30 g/L and proteinuria >3.5 g/day), and a few patients (n = 15) had proteinuria <1 g/day. The majority of patients (66%) were treated with ACE inhibitors and/or angiotensin receptor blockers.
As expected, we observed a linear relationship between, respectively, β2m and CysC and plasma creatinine (r = 0.69 and r = 0.86, respectively) and a hyperbolic relationship between β2m and CysC and eGFR-MDRD4. In univariable analysis, plasma urea, plasma albumin and proteinuria significantly predicted the relationship between CysC and eGFR-MDRD4 (respectively, P = <0.001, P = 0.003 and P = 0.049). In multiple regression analysis, both plasma urea and plasma albumin remained significant independent predictors (respectively, P < 0.001 and P = 0.016). At equal levels of CysC, patients with hypoalbuminaemia (plasma albumin <25 g/L) had higher eGFR-MDRD4 (rightward shift of curve, Figure 1) .
We used plasma β2m as a second marker of GFR. In univariable analysis, only plasma albumin significantly influenced the relationship between β2m and eGFR-MDRD4 (P = 0.024). In multiple regression analysis, plasma albumin remained an independent predictor (P = 0.027). In the presence of hypoalbuminaemia, there was again a rightward shift of the curve of the relationship between β2m and eGFR-MDRD4 (Figure 2 ). Thus, these results suggest that Data are means ± SD or medians (range). CysC, cystatin C; β2m, beta-2-microglobulin; eGFR-MDRD4, estimated GFR calculated using the abbreviated MDRD formula; eGFR-MDRD6, estimated GFR calculated using the original MDRD formula; eGFR-CKD-EPI, estimated GFR calculated using the CKD-EPI formula; ACEI, ACE inhibitor; ARB, angiotensin receptor blocker. Fig. 1 . Relationship between plasma cystatin C and eGFR-MDRD4 for different tertiles of plasma albumin (sAlb). Plasma albumin is an independent predictor of this relationship (P = 0.016).
Fig. 2.
Relationship between plasma beta-2-microglobulin and eGFR-MDRD4 for different tertiles of plasma albumin (sAlb). Plasma albumin is an independent predictor of this relationship (P = 0.027).
eGFR-MDRD4 provided higher estimates of GFR in patients with hypoalbuminaemia. We performed subgroup analyses, limiting the analyses to patients who were or were not treated with ACE inhibitors or angiotensin receptor blockers. Results were similar (data not shown).
The original MDRD formula for estimating GFR (eGFR-MDRD6) included plasma albumin and plasma urea as variables. Obviously, the relationship of eGFR-MDRD6 with eGFR-MDRD4 is thus dependent on plasma albumin concentrations.
We next analysed the relationship between eGFR-MDRD6 and β2m and CysC. In both univariable and multivariable regression, the relationship between β2m and eGFR-MDRD6 was not influenced by any of the parameters, including plasma albumin (P = 0.28, Figure 3 ). Results with CysC were different, somewhat to our surprise.
We observed a good correlation between CysC and eGFR-MDRD6 (r = 0.87). In univariable analysis, age (P = 0.043), proteinuria (P = 0.002), plasma albumin (P < 0.001) and plasma urea (P < 0.001) significantly influenced the relationship between CysC and eGFR-MDRD6. In multivariable analysis, both plasma albumin (P < 0.001) and plasma urea (P < 0.001) remained independent predictors, although the effect was small. Of note, for plasma albumin, the effect was now in the opposite direction with a leftward shift of the curve (Figure 4) .
We next evaluated the relationship between CysC and β2m. As expected for markers of GFR, we observed a high correlation between CysC and β2m (r = 0.87). In univariable analysis, age (P = 0.005), proteinuria (P = 0.002) and plasma albumin (P < 0.001) significantly influenced the relationship between CysC and β2m. In multivariable analysis, both age (P = 0.01) and plasma albumin (P < 0.001) remained independent predictors of this relationship. Variables included in this analysis were similar to those mentioned in the Materials and methods section, complemented with eGFR (both eGFR-MDRD4 and eGFR-MDRD6 were introduced once). At equal levels of β2m, patients with hypoalbuminaemia had lower levels of plasma CysC. The relationship between CysC and β2m is depicted in Figure 5 .
In recent years, other formulas for estimating GFR have been proposed. These include formulas based on serum creatinine concentration such as the CKD-EPI formula (CKD-EPI-Cr), as well as formulas based on serum CysC concentration (CKD-EPI-CysC) or a combination thereof (CKD-EPI-CysC-Cr). We evaluated these formulas in our patients. In multivariable analyses, plasma albumin proved an independent predictor of the relationship between both CysC and β2m and eGFR calculated by CKD-EPI-Cr. The relationship between CysC and eGFR calculated by CKD-EPI-CysC is invalid for this analysis. Analysing the relationship between β2m and eGFR calculated by CKD-EPI-CysC, we again found plasma albumin to be an independent predictor. Fig. 3 . Relationship between plasma beta-2-microglobulin and eGFR-MDRD6, calculated by using the original MDRD formula, for different tertiles of plasma albumin (sAlb). Plasma albumin does not influence this relationship (P = 0.62). Fig. 4 . Relationship between plasma cystatin C and eGFR-MDRD6 for different tertiles of plasma albumin (sAlb). Plasma albumin is an independent predictor of this relationship (P < 0.001).
Fig. 5.
Relationship between plasma cystatin C and plasma beta-2-microglobulin for different tertiles of plasma albumin (sAlb). Plasma albumin is an independent predictor of this relationship (P < 0.001). eGFR in the nephrotic syndrome Tables 3 and 4 summarize the results of eGFR estimates using various formulas, for patients with serum albumin levels above and below 30 g/L, respectively. In these tables, patients are grouped according to the level of eGFR calculated using the MDRD6 equation. Similar data were obtained when using classes of GFR based on serum β2m levels (Tables 5 and 6 ). The tables clearly illustrate that the various formulas provide rather similar results in patients with serum albumin levels >30 g/L, although as expected the GFR estimated by CKD-EPI formulas was higher in the higher categories of GFR. In contrast, the MDRD4 formula as well as the CKD-EPI formulas provided higher estimates of GFR in patients with serum albumin <30 g/ L, when compared with eGFR-MDRD6.
Discussion
We have evaluated the performance of the MDRD4 and MDRD6 formulas for estimating GFR in patients with proteinuric kidney disease. Our data indicate that these formu- Data are presented as median value (range). Median plasma albumin in this cohort was 40 g/L (range 30-47). β2m, category of serum β2m (mg/L) as measure of GFR; n, number of patients; MDRD4, eGFR calculated with the re-expressed four-variable MDRD equation; MDRD6, eGFR calculated with the re-expressed six-variable MDRD equation; CKD-EPI-Cr, eGFR calculated with creatinine-based CKD-EPI equation (Table 1) ; CKD-EPI-CysC, eGFR calculated with cystatin C-based CKD-EPI equation (Table 1) ; CKD-EPI-Cr + CysC, eGFR calculated with combined creatinine and cystatin C-based CKD-EPI equation (Table 1) ; K-W test, Kruskal-Wallis test.
las are not interchangeable in patients with low serum albumin levels. Notably, we observed that the relationship between eGFR-MDRD4 and the GFR markers CysC or β2m was influenced by plasma albumin levels. At equal levels of CysC or β2m, eGFR-MDRD4 was higher in patients with hypoalbuminaemia. In contrast, the relationship between eGFR-MDRD6 and β2m was not dependent on serum albumin levels. These discrepancies in performance between the MDRD4 and MDRD6 formula are clearly illustrated in Tables 3-6 , showing that eGFR estimated by the MDRD6 formula is consistently lower than values estimated by the MDRD4 formula in patients with low serum albumin levels. Tables 3 and 4 suggest that the MDRD6 formula is biased in patients with hypoalbuminaemia since the MDRD4 formula provides values that are closest to values derived by CysC-based formulas.
Could the MDRD6 formula be invalid in patients with a nephrotic syndrome? Integration of serum albumin levels in the MDRD6 formula provided a means to account for decreased creatinine generation in patients with malnutrition of chronic inflammation. Since hypoalbuminaemia in patients with a nephrotic syndrome is related to urinary albumin loss and not to malnutrition, the MDRD6 formula may be expected to underestimate GFR in patients with a nephrotic syndrome.
However, we suggest that our data indicate that the abbreviated MDRD4 formula overestimates GFR in patients with a nephrotic syndrome, due to altered tubular handling of creatinine. We observed that serum albumin levels influenced the relationship between eGFR-MDRD4 and CysC or β2m. At equal levels of CysC or β2m, eGFR-MDRD4 was higher in patients with hypoalbuminaemia. Both CysC and β2m are low-molecular-weight proteins that are filtered in the glomerulus without evidence of tubular secretion. Plasma levels of both CysC and β2m correlate well with GFR, both markers are used as estimates of GFR, and at least, β2m has been validated in patients with proteinuria [8] [9] [10] [11] [12] [13] . Based on these premises, the data indicate that eGFR-MDRD4 overestimates real GFR in patients with a nephrotic syndrome, which must be attributed to altered tubular handling of creatinine in patients with a nephrotic syndrome.
We have evaluated the recently developed CKD-EPI formulas. Our data suggest that also the creatinine-based CKD-EPI formula is less valid in patients with a nephrotic syndrome. This is not unexpected since alterations in the renal tubular handling of creatinine will affect all formulas that are merely based on serum creatinine levels as the sole laboratory parameter.
A closer look at our data and our additional analyses suggest that plasma β2m levels are a more consistent marker of GFR than levels of CysC.
Firstly, the effect of plasma albumin levels on the relationship between plasma β2m and eGFR-MDRD4 was quantitatively similar to the effect of plasma albumin levels on the relationship between endogenous creatinine clearance (ECC) and inulin clearance observed in our previous study [2] . In the present data, an eGFR-MDRD4 of 80 mL/ min/1.73 m 2 equalled a plasma β2m level of 2.10 mg/L in a patient with a plasma albumin of 40 g/L and 3.32 mg/L in a patient with a plasma albumin of 20 g/L (percentage overestimation 37%). In comparison, ECC of 80 mL/min equalled an inulin clearance of 57, respectively, 42 mL/min (percentage overestimation 26%) [2] .
Secondly, plasma β2m levels correlated with eGFR-MDRD6, independent from plasma albumin levels. We have previously suggested that eGFR-MDRD6 more accurately reflects inulin clearance in the nephrotic syndrome [2] .Thus far, plasma β2m has received a little attention as marker of GFR. Older studies observed a very high correlation between plasma β2m and GFR [12, 13] . The performance of β2m was disputed in other studies [14] . However, the latter study included patients with malignancies and systemic inflammation, conditions which may be associated with increased lymphocyte proliferation and thus generation of β2m. Our data suggest that a renewed interest in plasma β2m as a marker of GFR seems warranted.
Although CysC has been used more widely as a marker of GFR, its usefulness in clinical practice is debated. In a recent cross-sectional analysis of 3418 patients with kidney disease, Stevens et al. noted that factors such as age, gender, race, BMI, weight, plasma urea, diabetes, proteinuria and blood pressure influenced CysC independent of GFR [15] . Of note, in the latter study, serum albumin was negatively correlated with CysC, in apparent contrast with our findings showing lower CysC levels in patients with hypoalbuminaemia. There are clear differences between the studies. We have evaluated patients with often severe hypoalbumi- [16, 17] . Our data also point to changes in CysC production in patients with hypoalbuminaemia. The relationship between CysC and eGFR-MDRD6 was shifted to the left in patients with low albumin levels. Moreover, at equal levels of plasma β2m, CysC levels were lower in patients with hypoalbuminaemia. Our recent observations that subclinical hypothyroidism is frequent in patients with proteinuria may explain these findings [18] . Theoretically, formulas based on alternative markers such as CysC might be more advantageous. However, this will only be true if the production of this alternative marker is not changed in the nephrotic syndrome. Our observation of lower CysC levels in patients with hypoalbuminaemia already suggested that also CysC-based GFR formulas could be invalid in patients with a nephrotic syndrome. Analysis of the data confirmed this.
Literature data support our conclusions. Based on a study of 42 patients with proteinuria, we already suggested that creatinine was an invalid marker of GFR in patients with a nephrotic syndrome [2] . In this study, we showed that endogenous creatinine clearance as well as eGFR-MDRD4 overestimated GFR as measured by inulin clearance in patients with nephrotic syndrome. The study can be criticized for its small number of patients. Other studies provide supportive arguments. Several studies have reported glomerular hypofiltration due to a decreased filtration coefficient in patients with a nephrotic syndrome, despite normal levels of serum creatinine [19, 20] . Altered renal handling of creatinine in patients with proteinuria is supported by an analysis of data from the MDRD study, which showed an increased tubular secretion of creatinine in patients with glomerular diseases [21] .
Limitations of the study
Our conclusions are based on the assumption that plasma CysC and β2m are markers of GFR. We have not used inulin clearance or its alternatives to measure GFR. Therefore, our conclusions must be regarded as hypothesis generating and need further validation in larger studies in which golden standard techniques for measurement of GFR are used.
In conclusion, in patients with hypoalbuminaemia, we propose that estimates of GFR using creatinine-based formulas may be invalid. As a result, a clinically significant decrease of GFR may be overlooked in patients with a nephrotic syndrome. In daily clinical practice, one should be aware of the limitations of formulas for estimating GFR in patients with a nephrotic syndrome.
